2. Search Result
Search Result
Results for "

postmenopausal osteoporosis

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

1

Biochemical Assay Reagents

5

Peptides

2

Natural
Products

3

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3075
    pTH-Related Protein (1-34) (human,mouse,rat)

    pTHrP (1-34)

    		 Thyroid Hormone Receptor Inflammation/Immunology
    pTH-Related Protein (1-34) (human, mouse, rat), a fragment of parathyroid hormone-related protein, is an anabolic agent. pTH-Related Protein (1-34) (human, mouse, rat) can be used for postmenopausal osteoporosis study .
    pTH-Related Protein (1-34) (human,mouse,rat)
  • HY-123047
    Tibolone

    		Progesterone Receptor Androgen Receptor Estrogen Receptor/ERR Endocrinology
    Tibolone is a broad spectrum gonadal steroid agonist with progestagenic, androgenic, and estrogenic activities. Tibolone can be used for postmenopausal osteoporosis research .
    Tibolone
  • HY-15927
    4-Nitrophenyl β-D-glucopyranoside
    1 Publications Verification

    		 Biochemical Assay Reagents Metabolic Disease
    4-Nitrophenyl β-D-glucopyranoside is a chromogenic substrate for β-glucosidase. 4-Nitrophenyl β-D-glucopyranoside is converted to a colored product, p-nitrophenol that is easily detected spectrophotometrically at 405 nm when used in a β-glycosidase assay. 4-Nitrophenyl β-D-glucopyranoside is hydrolysed through intramolecular nucleophilic catalysis by the phosphate group in the 2-position. 4-Nitrophenyl β-D-glucopyranoside is promising for research of postmenopausal osteoporosis .
    4-Nitrophenyl β-D-glucopyranoside
  • HY-121528
    Nilestriol

    Nylestriol; EE3CPE

    		 Estrogen Receptor/ERR Endocrinology
    Nilestriol is a estriol derivative, which inhibits osteoporosis on ovariectomized rats or postmenopausal women .
    Nilestriol
  • HY-N2289
    2''-O-Rhamnosylicariside II

    		Others Others
    2''-O-Rhamnosylicariside II is a flavonoid glycoside compound and might be beneficial for improving postmenopausal osteoporosis.
    2''-O-Rhamnosylicariside II
  • HY-14752
    Ronacaleret

    SB 751689

    		 CaSR Metabolic Disease Endocrinology
    Ronacaleret (SB 751689) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret (SB 751689) is used for the study of postmenopausal osteoporosis .
    Ronacaleret
  • HY-15104
    Ronacaleret hydrochloride

    SB 751689A

    		 CaSR Metabolic Disease Endocrinology
    Ronacaleret hydrochloride (SB 751689A) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret hydrochloride (SB 751689A) is used for the study of postmenopausal osteoporosis .
    Ronacaleret hydrochloride
  • HY-123047R
    Tibolone (Standard)

    		Progesterone Receptor Androgen Receptor Estrogen Receptor/ERR Endocrinology
    Tibolone (Standard) is the analytical standard of Tibolone. This product is intended for research and analytical applications. Tibolone is a broad spectrum gonadal steroid agonist with progestagenic, androgenic, and estrogenic activities. Tibolone can be used for postmenopausal osteoporosis research .
    Tibolone (Standard)
  • HY-108685
    Alendronate sodium

    Alendronic acid monosodium salt

    		 Others Metabolic Disease Cancer
    Alendronate sodium is an orally active nitrogen-containing bisphosphonate. Alendronate sodium potently inhibits bone resorption. Alendronate sodium is used for the research of postmenopausal osteoporosis .
    Alendronate sodium
  • HY-122359
    Levormeloxifene

    L-Centchroman; L-Ormeloxifene

    		 Estrogen Receptor/ERR Endocrinology Cancer
    Levormeloxifene (L-Centchroman) is a selective estrogen receptor modulator (SERM), which prevents and ameliorates postmenopausal osteoporosis. Levormeloxifene causes multiple adverse gynecological effects .
    Levormeloxifene
  • HY-B0631
    Alendronic acid
    5 Publications Verification

    		 Others Cancer
    Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease .
    Alendronic acid
  • HY-123047S
    Tibolone-d5

    		Isotope-Labeled Compounds Estrogen Receptor/ERR Progesterone Receptor Androgen Receptor Endocrinology
    Tibolone-d5 is deuterium labeled Tibolone. Tibolone is a broad spectrum gonadal steroid agonist with progestagenic, androgenic, and estrogenic activities. Tibolone can be used for postmenopausal osteoporosis research .
    Tibolone-d5
  • HY-W698952S
    3β hydroxy Tibolone-d5

    		Isotope-Labeled Compounds Endocrinology
    3β hydroxy Tibolone-d5 is deuterium labeled Tibolone. Tibolone is a broad spectrum gonadal steroid agonist with progestagenic, androgenic, and estrogenic activities. Tibolone can be used for postmenopausal osteoporosis research .
    3β hydroxy Tibolone-d5
  • HY-A0037
    Lasofoxifene
    4 Publications Verification

    CP-336156

    		 Estrogen Receptor/ERR Inflammation/Immunology Cancer
    Lasofoxifene (CP-336156) is an orally active and selective estrogen receptor modulator (SERM). Lasofoxifene exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene can be used for research of breast cancer and postmenopausal osteoporosis .
    Lasofoxifene
  • HY-B0631S
    Alendronic acid-d6

    		Isotope-Labeled Compounds Cancer
    Alendronic acid-d6 is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease[1].
    Alendronic acid-d6
  • HY-A0038
    Lasofoxifene tartrate
    4 Publications Verification

    CP-336156 tartrate

    		 Estrogen Receptor/ERR Endocrinology Cancer
    Lasofoxifene (CP-336156) tartrate is an orally active and selective estrogen receptor modulator (SERM) . Lasofoxifene tartrate exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene tartrate can be used for the research of breast cancer and postmenopausal osteoporosis .
    Lasofoxifene tartrate
  • HY-111309
    LGD-2941

    		Androgen Receptor Endocrinology
    LGD-2941 is an orally active, potent and selective androgen receptor modulator. LGD-2941 shows excellent anabolic activity in muscle with reduced effect on the prostate in a rat model of hypogonadism. LGD-2941 also improves bone strength in a rat model of post-menopausal osteoporosis .
    LGD-2941
  • HY-135593
    LY88074 analog 1

    		Others Endocrinology
    LY88074 analog 1 is a benzothiophene compound with nitrogen-containing non-basic side chains, Compound 26, extracted from patent EP0747380A1. LY88074 analog 1 is an agent for alleviating the symptoms of post-menopausal symptoms, such as osteoporosis, cardiovascular related pathological conditions, and estrogen-dependent cancer. LY88074 analog 1 can be used alone or in combination with estrogen or progestin .
    LY88074 analog 1
  • HY-P0007
    Elcatonin

    Carbocalcitonin

    		 Drug Intermediate Metabolic Disease
    Elcatonin (Carbocalcitonin) is a synthetic analog of eel calcitonin. Elcatonin increases bone mineral density, inhibits bone resorption and processes a central analgesic effect .
    Elcatonin
  • HY-108044
    ONO-5334
    2 Publications Verification

    		 Cathepsin SARS-CoV Metabolic Disease
    ONO-5334 is a potent, selective and orally active cathepsin K inhibitor with Ki values of 0.10 nM, 0.049 nM and 0.85 nM for human, rabbit and rat cathepsin K, respectively. ONO 5334 is an effective antiviral compound against SAR-COV-2 virus activity with an EC50 value of 500 nM. ONO-5334 has the potential for the study of osteoporosis and COVID-19 disease .
    ONO-5334
  • HY-107245
    Segetalin B
    1 Publications Verification

    		 Estrogen Receptor/ERR Sirtuin RUNX Metabolic Disease
    Segetalin B, an orally active cyclopentapeptide found in Vaccaria segetalis, possesses estrogen-like activity. Segetalin B promotes mineralization of ovariectomized rat-derived bone marrow mesenchymal stem cells (BMSCs) in vitro and increases the level of osteocalcin, BMP-2, ALP, and SIRT1 activity. Segetalin B significantly decreases bone loss, inhibits calcium and phosphorus loss, elevates ALP activity, upregulates Runx2, Osterix, and SIRT1, and downregulates Notch intracellular domain (NICD), acetyl-NICD, and hairy and enhancer of split 1 (Hes1) in ovariectomized rats. Segetalin B is promising for research of post-menopausal osteoporosis (PMOP) .
    Segetalin B

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: